All Updates

All Updates

icon
Filter
Funding
SNIPR BIOME receives undisclosed funding from Bill & Melinda Gates Foundation
Human Gene Editing
Jun 28, 2024
This week:
Product updates
ABL Space Systems' RS1 rocket damaged during preflight testing
Space Travel and Exploration Tech
Yesterday
Funding
Industry news
Indian aerospace industry receives INR 10 billion budget to advance in space technology
Space Travel and Exploration Tech
Yesterday
Funding
Third Arc Bio raises USD 165 million in Series A funding to advance oncology and autoimmunity clinical programs
Precision Medicine
Yesterday
Partnerships
BostonGene collaborates with Sylvester Comprehensive Cancer Center to validate blood- and bone marrow-based assays for hematological cancers
Precision Medicine
Yesterday
Partnerships
Pinetree Therapeutics enters license agreement with AstraZeneca for preclinical EGFR degrader candidate
Precision Medicine
Yesterday
Partnerships
Oxford Nanopore Technologies and Plasmidsaurus partner to transform plasmid sequencing market
Precision Medicine
Yesterday
Partnerships
Altair partners with University of Nottingham to develop aerospace digital twin project
Digital Twin
Yesterday
Product updates
Tompkins Robotics launches ‘tSortPost,’ a flexible and scalable solution for parcel sorting
Logistics Tech
Yesterday
Partnerships
Kodiak Robotics partners with Atlas Energy Solutions to equip high-capacity trucks with autonomous technology
Truck Industry Tech
Yesterday
Funding
Plum Fintech raises GBP 16 million in Series B funding to expand product offerings
Retail Trading Infrastructure
Yesterday
Human Gene Editing

Human Gene Editing

Jun 28, 2024

SNIPR BIOME receives undisclosed funding from Bill & Melinda Gates Foundation

Funding

  • Danish biotech company SNIPR Biome has secured Bill & Melinda Gates Foundation financing. Details of the funding, including the total amount raised, were not disclosed.

  • The funding aims to advance SNIPR Biome's microbial gene therapy platform with a focus on managing Environmental Enteric Dysfunction (EED), a condition prevalent in pregnant women, by reducing gut entero-pathogen burden. The company aims to generate CRISPR-armed phages (CAPs) from its phage library that has a broad antibacterial activity on Escherichia coli and Klebsiella pneumoniae strains sourced from sites in low- and middle-income countries. SNIPR Biome’s existing CRISPR-armed phage cocktail (SNIPR001) will be leveraged in this project.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.